The company that gave India Augmentin also built the country’s largest private vaccine franchise. GlaxoSmithKline Pharmaceuticals Ltd has operated in India for one hundred years, evolving from an antibiotics supplier into a specialty and oncology innovator serving 230 million patients annually.
Most pharmaceutical companies in India measure their history in decades. GSK measures it in generations. When the entity that would become GlaxoSmithKline Pharmaceuticals began operations on the subcontinent, penicillin had not yet been discovered. The company that arrived as a colonial-era drug distributor survived independence, license raj, patent law reform, and the rise of Indian generics. It is still here. In FY2024–25, its centenary year, GSK India posted revenue of $446.8 million and net profit of Rs 9,190.5 million, serving 230 million patients.
That longevity is not accidental. The arithmetic of staying relevant for a hundred years in one of the world’s most competitive pharmaceutical markets requires something beyond brand recognition. It requires the willingness to cannibalize your own portfolio. The company that built its Indian business on Augmentin and Calpol and Betnovate now derives growing revenue from Nucala, Trelegy Ellipta, and Jemperli. The household names remain. But the future has shifted to biologics and oncology.
Thirty per cent of GSK’s global pharmaceutical volumes reach patients in India. That single number explains why the UK parent treats its Indian subsidiary not as a distribution outpost but as a strategic anchor. When GSK plc restructured globally, the India entity kept its manufacturing, its workforce, and its autonomy. As of March 2025, GSK India employed 3,113 people and dispatched 0.9 billion medicine packs annually from two manufacturing facilities.
India vaccinates more children each year than any other country, but the private vaccine market operates on different logic. Government procurement is price-driven and dominated by the Serum Institute and Bharat Biotech. The self-pay segment, where parents choose and pay for vaccines themselves, rewards trust, cold-chain reliability, and product breadth. GSK controls 40 per cent of this market by value. It is the single largest private-market vaccine company in India.
The franchise was built on paediatric immunization. Synflorix for pneumococcal disease, Infanrix Hexa for the six-in-one childhood schedule, and Rotarix for rotavirus gave GSK a portfolio that no competitor could match in combination breadth. In FY2020–21, the company distributed 5.1 million vaccine doses through the Indian private market alone. The paediatric portfolio was the foundation. But what changed the business was an adult vaccine.
In FY2022–23, GSK launched Shingrix, a recombinant adjuvanted vaccine for herpes zoster, in India. Adult vaccination was, for practical purposes, a category that barely existed in the Indian private market. Shingrix did not compete with existing products. It created a segment. The launch required GSK to build physician awareness of shingles as a clinical risk in older adults, train a field force on a disease most Indian doctors rarely diagnosed, and establish a two-dose compliance protocol in a market where single-dose convenience dominates. By FY2023–24, GSK India held the number-one position in private vaccines, with both the paediatric base and the nascent adult franchise contributing.
Open a medicine cabinet in any Indian household and there is a reasonable chance you will find at least one GSK product. Calpol, the paracetamol suspension, is what Indian mothers reach for when a child has a fever. Augmentin, the amoxicillin-clavulanate combination, is the antibiotic most physicians prescribe by name. Betnovate is shorthand for topical corticosteroids. Eltroxin is the default thyroid medication for millions of hypothyroid patients. These are not glamorous molecules. They are infrastructure.
But infrastructure ages. The question GSK India faced through the 2010s was whether a company whose identity rested on anti-infectives, analgesics, and dermatologicals could evolve into specialty therapeutics without losing its general-practice base. The answer came through a deliberate, multi-year portfolio transition. In FY2021–22, GSK India launched Nucala (mepolizumab), a biologic for severe eosinophilic asthma, and Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), a triple-combination inhaler for COPD. These were not generics of existing therapies. They were novel mechanisms requiring specialist prescribers, patient education, and cold-chain management for the biologic.
Then came oncology. Zejula (niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (dostarlimab), a PD-1 immunotherapy, moved GSK India into a therapeutic area it had never previously occupied. The progression tells you something about the company’s strategy: it did not attempt to become an oncology company overnight. It sequenced from mass-market generics to respiratory specialty to immuno-oncology, each step building the institutional capabilities needed for the next. By FY2023–24, GSK India ranked number one in dermatology and number two among all pharmaceutical MNCs in the country, reaching more than 200 million patients across its combined portfolio.
There is a test for whether a multinational pharmaceutical company is serious about a market: look at whether it builds factories there. Distribution offices are cheap. Regulatory teams are necessary. But a manufacturing plant is a twenty-year commitment in concrete and steel, and GSK has two in India.
The Nashik facility in Maharashtra has been the backbone of GSK India’s production for decades, manufacturing formulations across the anti-infectives, dermatology, and respiratory portfolios. It is the plant that produces Augmentin, Calpol, and Betnovate at a scale sufficient to dispatch 0.9 billion medicine packs a year. But Nashik alone could not support the portfolio expansion GSK was planning.
In FY2016–17, GSK commissioned a greenfield facility at Vemgal in Karnataka, near Bangalore. The Vemgal plant was built to modern GMP standards and expanded manufacturing capacity at a point when the company was preparing to launch specialty products that required different production capabilities. The investment was significant for an entity with revenue of $359.3 million in the year the plant came online. Two manufacturing sites for a company of GSK India’s scale is a deliberate choice: it provides redundancy, supports the growing product portfolio, and signals to the UK parent that the Indian subsidiary can handle production complexity beyond basic formulations.
The manufacturing footprint also supports the broader GSK supply chain. Some products reach Indian patients from GSK’s German facilities, but the domestic plants handle the volume. When the company states that 30 per cent of GSK’s global pharma volumes reach patients in India, that figure reflects both imported specialty products and the massive domestic production of established brands.
Sources: GSK India Annual Reports FY2014–15 through FY2024–25. Indian Patent Office (patent filing data). BSE India (listed entity data). OPPI member directory.